Break it Down: Neurotech’s human adult study tick of approval for cannabinoid drug

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Neurotech’s (ASX:NTI) vital approval to start its human pharmacokinetic study in Adelaide.

The company’s oral cannabinoid drug NTI164 is being developed as a therapeutic drug product for a range of neurological disorders where neuroinflammation is involved.

Tune in to get the latest.

While Neurotech is a Stockhead advertiser, it did not sponsor this content.